

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>4</sup> : <b>G01N 33/68, 33/53</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 89/12824</b> (43) International Publication Date: 28 December 1989 (28.12.89)</p>
<p>(21) International Application Number: PCT/GB89/00715 (22) International Filing Date: 26 June 1989 (26.06.89) (30) Priority data: 8815174.1 25 June 1988 (25.06.88) GB (71) Applicant (for all designated States except US): THE RO- WETT RESEARCH INSTITUTE [GB/GB]; Greenburn Road, Bucksburn, Aberdeen AB2 9SB (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : ROBINS, Simon, Peter [GB/GB]; 23 Middle Park, Inverurie, Aberdeenshire AB5 9QW (GB). (74) Agent: PATTULLO, Norman; Murgitroyd and Company, Mitchell House, 333 Bath Street, Glasgow G2 4ER (GB).</p>		<p>(81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (Eu- ropean patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: METHOD OF MONITORING COLLAGEN DEGRADATION</p> <p>(57) Abstract</p> <p>A method of monitoring collagen degradation, comprising assaying a biological fluid sample which contains a fragment of collagen including lysyl pyridinoline or hydroxylysyl pyridinoline or a substituted form thereof, and a method of determining the tissue origin of degraded collagen thereby.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Fasso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

### "Method of Monitoring Collagen Degradation"

This invention relates to a method of monitoring collagen degradation as a diagnostic aid in relation particularly to osteoporosis and rheumatoid arthritis.

Collagen is present in various form in all tissue. It has been shown (Fujimoto et al., (1978) Biochemistry, Biophysics Research Communication vol. 84, 52-57) that collagen has the form of amino acid chains cross-linked by pyridinoline. The pyridinium crosslinks are formed from three hydroxylysine residues, two from the terminal (non-helical) peptides of the collagen molecule that are enzymically converted to aldehydes before reaction and a third hydroxylysine situated in the helical portion of a neighbouring collagen molecule. Robins et al (Annals of the Rheumatic Diseases 1986, 45, 969-973) have described a technique for measurement of pyridinoline in urine by use of an antibody specific to pyridinoline and detected by enzyme-linked immunosorbent assay (ELISA). This technique, however gives a measure only of hydroxylysyl pyridinoline in the sample, and does not recognise lysyl deoxypyridinoline. The former is present in bone and tissue, and the latter in bone only. Thus the technique may indicate the occurrence of collagen degradation, indicating the presence of degenerative

disease, but without indicating the type of tissue concerned.

The present invention is based on the recognition that lysyl and hydroxylysyl pyridinoline are present in biological fluid such as urine, attached to fragments of the original amino acid chains, or to sugars. However, there is no certainty as to where the original chains will have broken. In virtually all cases, however, sufficient amino acids will be present to identify the type of tissue from which the particular collagen derived.

Accordingly, the present invention provides a method of monitoring collagen degradation, comprising assaying a biological fluid sample which contains a fragment of collagen including lysyl pyridinoline or hydroxylysyl pyridinoline or a substituted form thereof.

Further according to the present invention there is provided a method of determining the tissue origin of degraded collagen, comprising assaying a biological fluid sample to determine the amount of lysyl pyridinoline or hydroxylysyl pyridinoline containing at least one substituents specific for the origin of the collagen degraded.

From another aspect, the invention resides in an antibody, preferably monoclonal, which is specific to a fragment of collagen which fragment comprises lysyl or hydroxylysyl pyridinoline having at least one amino acid attached thereto.

From another aspect, the invention resides in an antibody, preferably monoclonal, which is specific to a fragment of collagen which fragment comprises hydroxylysyl pyridinoline having a sugar residue attached thereto.

Preferably the pyridinoline is substituted with sections of original amino acid chains.


Preferably, said short sections of amino acid chains each comprise from one to five amino acids.

Preferably the sugar is linked to pyridinoline by glycosylation with galactose or with glucose and galactose.


The collagen may suitably be associated with bone or cartilage.

Embodiments of the invention will now be described in further detail by way of example.


Collagen has the general structure:



where A's, B's and C's are amino acids and P is lysyl or hydroxylysyl pyridinoline or glycosylated hydroxylysyl pyridinoline. When present in biological fluid, for example, urine, the A, B and C chains are broken and of indeterminate length. The invention is based on the fact that collagen from a specific body tissue will give rise in the biological fluid sample to the presence of




where A, B and C are short chains of from one to five amino acids, A, B, and C always being present, and Ax, Ay, Bx, By, Cx, Cy etc. are further parts of the original chains which may or may not be present. Further, A, B and C are specific to a particular tissue of origin. Therefore, this aspect of the invention operates on the unit




In another aspect of the invention X may be a glycosylated hydroxylysyl pyridinoline which may or may not have amino acids attached.

Hydroxylysine residues in the helix are glycosylated by addition of sugar groups at their hydroxyl group. Where formation of the pyridinoline (Pyd) crosslink involves a glycosylated hydroxylysine, a glycosylated crosslink will be produced. The crosslink analogue, lysyl-pyridinoline, formed by reaction with a lysine residue in the helix cannot form any glycosylated derivatives as it lacks the side-chain hydroxyl group.

There are two types of glycosylation, either galactose (Gal) alone or the disaccharide, glucosyl-galactose (Gal.Glc). Thus, there are two possible forms of glycosylated hydroxylysyl pyridinoline as shown below, Pyd-Gal and Pyd-Gal.Glc.



Pyd-Gal (I)



Pyd-Gal.Glc (II)

The relative proportion of mono- to di-saccharide derivatives of hydroxylysine varies with different tissues. For the main tissues of interest (i.e. those that contain pyridinoline) cartilage contains almost entirely Gal.Glc, whereas in bone collagen the monosaccharide predominates.

Both the mono- and di-saccharide derivatives of pyridinoline

(structures I and II) have been isolated from human urine and identified. These components are present normally in urine but have been shown to be present in increased amounts in various bone disorders and in arthritic disease.

The main points of interest in these findings are:

1. The components are present in urine without hydrolytic treatment and an assay procedure would therefore be applicable directly to urine.
2. Assays of the two components will give some tissue-specific information on collagen breakdown. Measurement of Pyd-Gal will provide an index of bone collagen resorption: Pyd-Gal.Glc amounts in urine are primarily indicative of bone or cartilage degradation, and the relative amounts of Pyd-Gal and Pyd-Gal.Glc will provide information on the relative extent of bone and cartilage degradation.
3. The presence of the sugar groups may increase the antigenicity (ease with which good antibodies can be raised) of the components. The sugar portions will form part of the antibody recognition sites so that antibodies specific for each structure can be produced.

Two types of tissue of particular interest are bone and cartilage. The presence of degradation of bone collagen alone is an indicator of osteoporosis and other bone disorders, while the presence of degradation of both bone collagen and cartilage collagen is an indicator of arthritic disorders or diseases.

In general, the invention can be carried out by following the steps:



1. Identify a particular X of interest in biological fluid.
2. Isolate X.
3. Attach X to a suitable protein.
4. Inject the product of 3 into a host animal and raise antibody.
5. Use this antibody in ELISA or other suitable assay technique.

More specific examples of the invention will now be given.

Schemes 1 and 2 summarise the strategies for isolating crosslink-containing fragments from urine and give details of the components being isolated. Variations on these Schemes are detailed below.

#### EXAMPLE 1

##### Method

- a. Urine samples containing high concentrations of total pyridinium crosslinks were collected from patients with disorders involving either increased bone turnover (hyperparathyroidism) or increased cartilage and bone degradation (rheumatoid arthritis).
- b. A total of 1.0-1.5l of urine was freeze-dried, redissolved in 0.2 M acetic acid and was subjected to gel filtration chromatography in batches using a 2.6 x 140cm column of Biogel P2.
- c. Selected fractions containing pyridinium crosslink derivatives were re-chromatographed by reversed-phase HPLC using a C18 support and elution with a mobile phase

containing acetonitrile. The peptides were further purified by ion-exchange HPLC using DEAE- and SP-5PW columns.

d. The isolated components were characterized by fast atom bombardment mass spectrometry and amino acid sequence analysis; glycosylation sites were identified by gas-liquid chromatography of alkali hydrolysates of the peptides.

e. With a knowledge of the amino acid sequences around the crosslink sites in bone and cartilage, the tissues of origin of the peptides isolated from urine were established. A number of three peptides containing the core sequence representative of different tissues was chosen for raising antibodies.

f. Each of the purified peptides (1  $\mu$ mol) were covalently attached to ovalbumin (0.25  $\mu$ mol) using N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride.

g. Balb/c mice were immunized with the ovalbumin conjugates and monoclonal antibodies were produced after fusion with Ag8.653 myeloma cells. Positive clones were detected by ELISA using microtube plates coated with the peptides attached to gelatin by reaction with a different carbodiimide reagent N-cyclohexyl-N'-2-(4'-methylmorpholinium) ethyl carbodiimide-p-toluene sulphonate.

The monoclonal antibodies so produced may be used in immunoassay tests for the diagnosis and monitoring of various types of bone disorders and degenerative joint diseases.

Example 2

## Method

- Step 1. Urine (300ml), concentrated to one tenth its original volume, was chromatographed on a column (3.0 x 100cm ) of sephadex G25M with 0.2M-acetic acid as eluant. The fractions between 540 and 630ml ( $V_e/V_0=1.6-1.9$ ) that contained approx. 60% of the characteristic pyridinium crosslink fluorescence were pooled and freeze-dried.
- Step 2. The fraction from Step 1 (280mg) was re-chromatographed on a column (1.7 x 140cm) of Sephadex G10 eluted with 0.2M-acetic acid to separate the crosslinking components from amino acids and other small-M material. The fractions were monitored by fluorescence (Ex 295nm; Emm 400nm) and material that eluted between 105 and 121ml ( $V_e/V_0 = 1.1-1.3$ ) was pooled and evaporated to dryness.
- Step 3. The fraction from Step 2 was subject to cation-exchange chromatography on a column (0.9 x 15cm) of sulphonated polystyrene resin beads (5 $\mu$ ) crosslinked (8%) with divinyl benzene (Locarte Co Ltd, London; Cat No LA 48/08) run at 56 C and eluted with 67mM sodium citrate buffer, pH 3.84. Fractions of 5ml were collected and appropriate fractions were desalted on a column (1.7 x 50cm) of Sephadex G10 and freeze-dried.

In this system, Pyd-Gal (I) eluted between 91 and 105min and pyd-Gal.Glc (II) eluted between 41 and 50min.

Final purification of I and II was reversed-phase HPLC on a column (0.9 x 25cm) of Rosil C<sub>18</sub> packing (3 $\mu$ ) eluted with 0.1% heptafluorobutyric acid and a linear gradient from 15 to 30% acetonitrile over 30 min. (I) and (II) eluted at 17.3 and 16.9min respectively.

## CHARACTERISATION

### 1. Hydrolysis characteristics

Mild acid hydrolysis (0.1M HCl at 108 °C for 12h) converted Pyd-Gal.Glc (II) completely into a mixture of Pyd-Gal (I) and pyridinoline (Pyd). Hydrolysis of Pyd-Gal (I) in 2M HCl at 108 °C for 8h effected complete conversion of this component to Pyd. This behaviour is characteristic for these types of compound and has been noted previously for the interconversion of hydroxylysine glycosides to hydroxylysine.

### 2. Composition

On hydrolysis with strong mineral acid, both compounds (I) and (II) produced Pyd with no other amino acids detected in the hydrolysates. The carbohydrate compositions were determined by gas-liquid chromatography of methylated derivatives, after hydrolysis in 2M H<sub>2</sub>SO<sub>4</sub> and reduction with sodium borohydride. Based on these results and determination of the amounts of crosslink by HPLC, the molar ratios were:

Component I    Pyridinoline (1.0); Galactose (0.9)

Component II    Pyridinoline (1.0); Galactose (0.8); Glucose (0.9)

The results above therefore confirm that the structures of compounds I and II are as shown earlier.

In addition to the above, an associated derivative, termed 'X', that eluted between 184 and 195min at Step 3, has been isolated. This component contains Pyd and is increased in amount in patients with bone disorders.

Immunoassays for these components will be developed precisely as described for the peptides by conjugation to ovalbumin through their amino or carboxyl groups.

Modification and improvements may be incorporated without departing from the scope of the invention.

12

SCHEME 1

URINE

Concentrated to one tenth vol.



STEP 1

Gel Filtration on Sephadex-G25M



STEP 2

Smaller components fractionated by  
gel filtration on Sephadex-G10

STEP 3

Separation and purification by  
ion-exchange chromatography and HPLCCharacterisation of glycosylated  
dervatives:

Pyd.Gal.Glc (I), Pyd.Gal (II)

SCHEME 2

URINE

Concentrated to one tenth vol.



STEP 1

Gel filtration on Sephadex-G25M



STEP 2

Larger Components fractionated by  
gel filtration on Biogel-P6

STEP 3

Reversed-phase HPLC with TFA/acetonitrile

Isolation of three crosslinked peptide  
components (III, IV & V) with retention  
times of 27.2, 31.7 and 36.2 min  
respectively

STEP 4

Purification of IV and V by HPLC with HFBA/  
acetonitrile

STEP 5

Purification of III by ion-exchange  
chromatography on a DEAE-5PW column and by  
further HPLC (as step 4)

CLAIMS

1. A method of monitoring collagen degradation, comprising assaying a biological fluid sample which contains a fragment of collagen including lysyl pyridinoline or hydroxylysyl pyridinoline or a substituted form thereof.
2. A method as claimed in Claim 1, wherein the said pyridinoline is substituted with sections of amino acid chains.
3. A method as claimed in Claim 1, wherein the collagen fragment contains glycosylated hydroxylysyl pyridinoline.
4. A method as claimed in Claim 3, wherein the hydroxylysyl pyridinoline is glycosylated with galactose.
5. A method as claimed in Claim 3, wherein hydroxylysyl pyridinoline is glycosylated with a combination of galactose and glucose.
6. A method as claimed in any one of the preceding Claims, wherein the biological fluid sample is urine.
7. A method as claimed in any of the preceding Claims, wherein the assay includes purification of the sample.
8. A method as claimed in Claim 7, where in the purification comprises at least one technique selected from gel filtration chromatography, reversed - phase high pressure liquid chromatography and ion-exchange liquid chromatography.
9. A method as claimed in Claim 8, wherein the purification products are quantified.



10. A method as claimed in Claim 9, wherein the products are quantified by a technique selected from fluorescence, ultra-violet spectroscopy, electrochemical detection and capillary zone electrophoresis.

11. A method as claimed in any one of the preceding Claims, wherein the sample is assayed using an antibody which is specific to the lysyl pyridinoline or hydroxylysyl pyridinoline or substituted form thereof.

12. A method as claimed in Claim 11, wherein the antibody is monoclonal.

13. A method of determining the tissue origin of degraded collagen, comprising assaying a biological fluid sample to determine the amount of lysyl pyridinoline or hydroxylysyl pyridinoline containing at least one substituent specific for the origin of the collagen degraded.

14. A method as claimed in Claim 13, wherein the substituents are peptides.

15. A method as claimed in Claim 13, wherein the substituent is a glycoside.

16. A method as claimed in Claim 15, wherein the substituent is galactose.

17. A method as claimed in Claim 15, wherein the substituent is a combination of galactose and glucose.

18. An antibody which is specific to a fragment of collagen which fragment comprises lysyl or hydroxylysyl pyridinoline having at least one amino acid attached thereto.

19. An antibody which is specific to a fragment of collagen which fragment comprises hydroxylysyl pyridinoline having a sugar residue attached thereto.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB89/00715

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : G 01 N 33/68, 33/53																							
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched †</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System</td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px;">G 01 N</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *</div>			Classification System	Classification Symbols	IPC <sup>4</sup>	G 01 N																	
Classification System	Classification Symbols																						
IPC <sup>4</sup>	G 01 N																						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT*</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 60%; padding: 5px;">Citation of Document, †† with indication, where appropriate, of the relevant passages ‡</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. ‡</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P,X</td> <td style="padding: 5px;">WO, A1, 89/04491 (WASHINGTON RESEARCH FOUNDATION) 18 May 1989 see in particular pages 12-14, the claims and page 4, lines 16-22 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2, 6-14, 18</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Analytical Chemistry, vol. 169, 1988, pages 197-203, D. Black et al.: "Quantitative Analysis of the Pyridinium Crosslinks of Collagen in Urine Using Ion-Paired Reversed-Phase High-Performance Liquid Chromatography", see pages 197-99 and 202 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">2,11,12,14</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 6-10, 13</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Annals of the Rheumatic Diseases, vol. 45, 1986, pages 969-973, S.P. Robins et al.: "Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease", see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">2, 7-12, 14</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,6,13,18</td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 5px;">.../...</td> </tr> </tbody> </table>			Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡	Relevant to Claim No. ‡	P,X	WO, A1, 89/04491 (WASHINGTON RESEARCH FOUNDATION) 18 May 1989 see in particular pages 12-14, the claims and page 4, lines 16-22 --	1,2, 6-14, 18	Y	Analytical Chemistry, vol. 169, 1988, pages 197-203, D. Black et al.: "Quantitative Analysis of the Pyridinium Crosslinks of Collagen in Urine Using Ion-Paired Reversed-Phase High-Performance Liquid Chromatography", see pages 197-99 and 202 --	2,11,12,14	X	--	1, 6-10, 13	Y	Annals of the Rheumatic Diseases, vol. 45, 1986, pages 969-973, S.P. Robins et al.: "Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease", see the whole document --	2, 7-12, 14	X	--	1,6,13,18	.../...		
Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡	Relevant to Claim No. ‡																					
P,X	WO, A1, 89/04491 (WASHINGTON RESEARCH FOUNDATION) 18 May 1989 see in particular pages 12-14, the claims and page 4, lines 16-22 --	1,2, 6-14, 18																					
Y	Analytical Chemistry, vol. 169, 1988, pages 197-203, D. Black et al.: "Quantitative Analysis of the Pyridinium Crosslinks of Collagen in Urine Using Ion-Paired Reversed-Phase High-Performance Liquid Chromatography", see pages 197-99 and 202 --	2,11,12,14																					
X	--	1, 6-10, 13																					
Y	Annals of the Rheumatic Diseases, vol. 45, 1986, pages 969-973, S.P. Robins et al.: "Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease", see the whole document --	2, 7-12, 14																					
X	--	1,6,13,18																					
.../...																							
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: †</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>																							
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search 7th September 1989</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report 29. 09. 89</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority  EUROPEAN PATENT OFFICE</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer  T.K. WILLIS</td> </tr> </table>			Date of the Actual Completion of the International Search 7th September 1989	Date of Mailing of this International Search Report 29. 09. 89	International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  T.K. WILLIS																	
Date of the Actual Completion of the International Search 7th September 1989	Date of Mailing of this International Search Report 29. 09. 89																						
International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  T.K. WILLIS																						

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Chemical Abstracts, vol. 105, no. 7, 18 August 1986, (Columbus, Ohio, US), Schuppan D. et al.: "Radioimmunoassay for the carboxy-terminal cross-linking domain of type IV (basement membrane) procollagen in body fluids. Characterization and application to collagen type IV metabolism in fibrotic liver disease", see page 463, abstract 58896z, & J. Clin. Invest. 1986, 78(1), 241-8 (Eng). see the whole abstract	2, 7-12, 14
X	Chemical Abstracts, vol. 99, no. 19, 7 November 1983, (Columbus, Ohio, US), Fujimoto Daisaburo et al.: "Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine", see page 446, abstract 156368f, & J. Biochem. (Tokyo) 1983, 94(4), 1133-6 (Eng).	1, 6
A	Biochem. J., vol. 207, 1982, pages 617-620 S.P. Robins: "An enzyme-linked immunoassay for the collagen cross-link pyridinoline",	11, 12, 18
A	Cardiovascular Research, vol. 21, 1987, pages 161-168, M.A. Whittle et al.: "Biochemical investigation of possible lesions in human aorta that predispose to dissecting aneurysms: pyridinoline crosslinks", see pages 161, 164 and Discussion, in particular page 166, right column.	1, 13, 18
A	Analytical Biochemistry, vol. 147, 1985, pages 258-264, Zeenat Gunja-Smith: "An Enzyme-Linked Immunosorbent Assay to Quantitate the Elastin Crosslink Desmosine in Tissue and Urine Samples", see the whole document	1, 6
O,X	Scottish Medical Journal, vol. 33, (1988):4, page 317, Scottish Society for Experimental Medicine, Meeting on 13th May 1988 see the right col., second complete abstract	1, 6

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

PCT/GB89/00715

SA 29658

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office (EPO) file on 03/03/89  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8904491	18-05-89	None	